MERCK & CO INC

Merck & Immutep’s new immunotherapy, eftilagimod alfa, boosts KEYTRUDA survival in low‑PD‑L1 NSCLC but halted TACTI‑004, showing the promise and risk of combo trials.

FDA approves KEYTRUDA or QLEX with Padcev for cisplatin‑ineligible muscle‑invasive bladder cancer, offering new neoadjuvant/adjuvant options backed by KEYNOTE‑B15 data.

Merck & Co. (MRK) remains a core dividend asset in SCHD, offering steady 3.2% yield, 12‑year payout growth, strong earnings, and a growing oncology pipeline—ideal for income‑seeking investors.

Merck & Co. stocks offer dividend‑centric investors steady yields amid shifting healthcare reimbursement. This deep dive reveals operational efficiencies, ROIC strength, and digital health gains, highlighting how the company balances income, growth,…

Merck’s stock climbs as investors favor defensive healthcare amid easing geopolitics and oil volatility, showing robust earnings and a resilient pipeline.

Merck’s 29 June 2026 share rise shows a resilient healthcare stock: strong valuation, growth‑oriented R&D, value‑based care strategy, and cost‑efficient operations that boost investor confidence.

Merck’s MRK gains amid market rotation, driven by its cardiometabolic, oncology, vaccine, and cell‑therapy breakthroughs—showing resilience and value for investors.

Merck’s modest stock rise on a weak day is fueled by its new Alger Russell Innovation Index spot, attractive macro‑valuation, and oncology gains – a clear value play for healthcare investors.

Merck expands its animal‑health reach with a poultry automation deal, a gene‑therapy partnership for companion animals, and stronger precision‑oncology diagnostics—boosting growth while offsetting patent cliffs.

Merck & Co. navigates a Frankfurt Stock Exchange outage while advancing mRNA cancer vaccines and space‑based drug trials, showcasing resilience and innovation.